Companion Diagnostics Market
The global companion diagnostics market size was valued at USD 1.2 Bn in 2025 and is projected to reach USD 3.6 Bn by 2036, expanding at a CAGR of 10.4% from 2026 to 2036. The market growth is driven by innovations in genomic and molecular testing technologies and the growing need for targeted therapies in oncology.
👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=387
Market Overview
Companion diagnostics refer to medical devices or tests that aim to improve the effectiveness of certain therapeutic drugs through the discovery of patients who are most likely to respond positively to a particular course of treatment. These diagnostics play a vital role in the personalized medicine era, where treatments are customized based on individual patient characteristics instead of the conventional approach, where everyone gets the same treatment. Essentially, the main purpose of companion diagnostics is to scrutinize biomarkers – be they proteomic, genetic, or other molecular patterns that help predict the patients’ response to a specific drug.
The importance of companion diagnostics is most visible in oncology, where they help in choosing the most appropriate targeted therapies. The tests that find specific genetic mutations in cancer cells can help oncologists to prescribe drugs that have a higher probability of achieving the desired effects in patients. Apart from improving the effectiveness of treatments, this also reduces the risk of side effects caused by the use of drugs that are not effective.
Analysts’ Viewpoint
The companion diagnostics market is experiencing substantial growth, primarily driven by the widespread adoption of personalized medicine and tailored treatment approaches. Companion diagnostics are basically the healthcare providers’ most important tools in figuring out which patients will benefit the most from a certain therapeutic drug, thus not only increasing the treatment efficacy but also minimizing the side effects. As cancer is the major focus of this sector, with biomarkers playing an increasingly important role in patient stratification, the demand for companion diagnostics is projected to go up.
In addition, the development of genomic technologies and the growing number of targeted therapies are driving the market growth, with many pharmaceutical companies partnering in the creation of companion diagnostics along with their drugs. Moreover, regulatory support, especially from the FDA and EMA, is a significant factor in market boosting, as these agencies grant diagnostic devices that go hand in hand with new therapeutics considerably faster market access.
Analysis of Key Players
Strong investments in molecular diagnostic technologies, biomarker development, and strategic collaborations with pharmaceutical firms characterize the competitive landscape.
Leading companies operating in the global companion diagnostics market include:
• Roche Diagnostics
• Thermo Fisher Scientific
• Agilent Technologies
• Abbott Laboratories
• QIAGEN
• BioMérieux
• Danaher Corporation
• Illumina Inc.
• Siemens Healthineers
• Myriad Genetics
• Guardant Health
• Foundation Medicine
• Bio-Rad Laboratories
• Exact Sciences Corporation
• NeoGenomics Laboratories
• Invivoscribe
• Sysmex Corporation
• F. Hoffmann-La Roche Ltd.
• ArcherDX
• Other Prominent Players
Strategic partnerships between pharmaceutical and diagnostic companies remain a major industry trend. Several market participants are actively focusing on co-development agreements to improve patient stratification and enhance treatment efficacy.
Recent Developments (2025-2026)
• In February 2026, Roche Diagnostics announced expansion of its oncology companion diagnostic portfolio with advanced genomic profiling solutions aimed at improving precision oncology outcomes.
• In October 2025, Thermo Fisher Scientific strengthened its molecular diagnostics capabilities through expanded partnerships with biopharmaceutical companies for companion diagnostic development.
• In June 2025, QIAGEN launched new biomarker testing solutions to support precision medicine and targeted cancer therapies.
• In March 2025, Illumina expanded its next-generation sequencing applications to accelerate companion diagnostic development for oncology and rare diseases.
👉 Discuss Implications for Your Industry Request Sample Research Report PDF@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=387
Challenges
• High Development Costs: Companion diagnostic development requires substantial R&D investments and regulatory approvals.
• Complex Regulatory Pathways: Co-approval requirements for drugs and diagnostics can delay commercialization timelines.
• Limited Reimbursement: In several healthcare systems, reimbursement challenges limit diagnostic accessibility.
• Biomarker Validation Issues: Ensuring biomarker reliability and clinical relevance remains a significant hurdle.
Opportunities
• Cancer Diagnostics Expansion: Rising incidence of cancer creates strong demand for biomarker-driven testing.
• Rare Disease Applications: Companion diagnostics present significant opportunities in genetic and orphan diseases.
• Liquid Biopsy Growth: Increasing adoption of minimally invasive liquid biopsy testing offers strong market potential.
• Emerging Markets: Expanding healthcare infrastructure in developing economies supports market penetration.
Market Segmentation
➤ By Technology
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS) (Fastest Growing Segment)
• Immunohistochemistry (IHC)
• In Situ Hybridization (ISH)
• Others
➤ By Indication
• Oncology (Leading Segment)
• Neurological Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Rare Genetic Disorders
➤ By End-user
• Hospitals & Diagnostic Laboratories
• Pharmaceutical & Biopharmaceutical Companies
• Research Institutes
➤ By Region
• North America (Leading Region – 37.2% Market Share in 2025)
• Europe
• Asia Pacific (Fastest Growing Region)
• Latin America
• Middle East & Africa
Conclusion
The companion diagnostics market is emerging as a foundational pillar of precision medicine and personalized healthcare. As pharmaceutical companies increasingly focus on targeted therapies, companion diagnostics will become essential for improving treatment efficacy and patient outcomes. Through 2036, advancements in genomic technologies, biomarker discovery, and AI-driven diagnostics are expected to redefine disease management and accelerate market expansion globally.
👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=387
Frequently Asked Questions
• How big was the global companion diagnostics market in 2025?
The global companion diagnostics market was valued at US$ 1.2 Bn in 2025
• What is the projected size of the companion diagnostics Industry by 2036?
The global companion diagnostics Industry is projected to cross US$ 3.6 Bn by the end of 2036
• What are the factors driving the companion diagnostics market?
Innovations in genomic and molecular testing technologies and growing need for targeted therapies in oncology
• What is the companion diagnostics market expected to grow during the forecast period?
The global companion diagnostics market is anticipated to grow at a CAGR of 10.4% from 2026 to 2036
• Which region is expected to dominate the companion diagnostics market during the forecast period?
North America is expected to account for the largest share from 2026 to 2036
Explore Latest Research Reports by Transparency Market Research:
Flow Chemistry Market – https://www.transparencymarketresearch.com/flow-chemistry-market.html
Data Center Infrastructure Management Market – https://www.transparencymarketresearch.com/data-center-infrastructure-management-market.html
Building Automation and Control System Market – https://www.transparencymarketresearch.com/building-automation-control-system-market.html
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany, NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com
This release was published on openPR.